GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » EPS without NRI

bluebird bio (bluebird bio) EPS without NRI

: $-0.74 (TTM As of Sep. 2023)
View and export this data going back to 2013. Start your Free Trial

bluebird bio's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.66. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.74.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 30.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for bluebird bio's EPS without NRI or its related term are showing as below:

BLUE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -65.7   Med: -31   Max: 30.8
Current: 30.8

During the past 12 years, bluebird bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 30.80% per year. The lowest was -65.70% per year. And the median was -31.00% per year.

BLUE's 3-Year EPS without NRI Growth Rate is ranked better than
79.72% of 1297 companies
in the Biotechnology industry
Industry Median: 4.5 vs BLUE: 30.80

bluebird bio's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.66. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.74.

bluebird bio's EPS (Basic) for the three months ended in Sep. 2023 was $-0.66. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.74.


bluebird bio EPS without NRI Historical Data

The historical data trend for bluebird bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.64 -10.06 -9.02 -7.89 -3.34

bluebird bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.96 0.38 0.21 -0.67 -0.66

Competitive Comparison

For the Biotechnology subindustry, bluebird bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bluebird bio PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, bluebird bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where bluebird bio's PE Ratio without NRI falls into.



bluebird bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


bluebird bio  (NAS:BLUE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


bluebird bio EPS without NRI Related Terms

Thank you for viewing the detailed overview of bluebird bio's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


bluebird bio (bluebird bio) Business Description

Traded in Other Exchanges
Address
455 Grand Union Boulevard, Somerville, MA, USA, 02145
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Executives
Richard A Colvin officer: Chief Medical Officer 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain officer: President of SGD C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk officer: Chief Financial Officer 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima officer: Chief Commercial Officer, SGD C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson director 85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio officer: Chief Business & Legal Officer C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman director 1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole officer: SVP, Secy. & General Counsel C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann officer: Chief Regulatory Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton director 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman officer: Chief Financial Officer C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten officer: Chief Accounting Officer 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid director 455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145